FDA Approves ZOLADEX — TerSera Therapeutics LLC

# FDA Approves ZOLADEX (Goserelin Acetate) for TerSera Therapeutics TerSera Therapeutics LLC has received FDA approval for ZOLADEX (goserelin acetate), a subcutaneous treatment that establishes the company's entry into the hormone therapy market with potential applications in oncology and endocrinology. The approval positions TerSera to compete in the GnRH agonist space, a significant category for prostate cancer, breast cancer, and endometriosis management.